Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma

Fig. 6

Regulation of c-Myc by the FGF/FGFR system in cancer. Activation of the FGFR signaling regulate c-Myc activity at both transcriptional and post-translational level. A FGFR phosphorylation activates transcription factors such as ERK1/2 and STAT3 that promote MYC transcription. Also, FGFR1 fusion kinase in the cytoplasm can activate STAT5 that contributes to MYC transcription. Alternatively, the truncated form of the FGFR1 fusion kinase generated from the cleavage by granzyme B can translocate to the nucleus where it recognises specific binding sites in the MYC locus having a direct effect on MYC expression. B FGFR phosphorylation activates the kinase activity of ERK1/2 that in turn leads to c-Myc S62 phosphorylation and c-Myc stabilization. At the same time, FGFR also triggers PI3K/AKT pathway that inhibits GSK-3β kinase, thus preventing c-Myc T58 phosphorylation and c-Myc proteasomal degradation

Back to article page